目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNITS CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: MARKET
2.10 RECESSION IMPACT

3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 8 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 51)
4.1 MULTIPLEX ASSAYS MARKET OVERVIEW
FIGURE 14 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
4.2 MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 15 CONSUMABLES PRODUCT & SERVICE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
4.3 MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 16 PROTEIN MULTIPLEX ASSAYS TYPE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
4.4 MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 17 FLOW CYTOMETRY TECHNOLOGY TO ACCOUNT FOR LARGEST MARKET SHARE
4.5 MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 18 RESEARCH & DEVELOPMENT APPLICATION TO ACCOUNT FOR LARGER MARKET SHARE
4.6 MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES END USER SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
4.7 MARKET: REGIONAL GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing use of multiplex assays in companion diagnostics
5.2.1.2 Increasing advantages over singleplex and traditional assays
5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, IN 2021, 2030, AND 2045
TABLE 1 TOTAL HEALTH EXPENDITURE DUE TO DIABETES (20-79 YEARS) IN 2021, BY COUNTRY
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
TABLE 3 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR DIAGNOSIS OF SARS-COV-2
5.2.2 RESTRAINTS
5.2.2.1 Rising costs of equipment
5.2.2.2 Growing number of stringent regulations and standards
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics
5.2.3.2 Rising need for high-throughput and automated systems
5.2.4 CHALLENGES
5.2.4.1 Increasing dearth of skilled professionals
TABLE 4 NUMBER OF LAB TECHNOLOGISTS AND TECHNICIANS IN US, 2020
5.3 CUSTOMIZATION DATA
TABLE 5 MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE (Page No. - 63)
6.1 INTRODUCTION
TABLE 6 MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
6.2 PRIMARY NOTES
6.2.1 KEY INDUSTRY INSIGHTS
6.3 CONSUMABLES
6.3.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
TABLE 7 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
6.4 INSTRUMENTS
6.4.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
TABLE 9 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
TABLE 11 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 12 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 MULTIPLEX ASSAYS MARKET, BY TYPE (Page No. - 69)
7.1 INTRODUCTION
TABLE 13 MARKET, BY TYPE, 2020-2027 (USD MILLION)
7.2 PROTEIN MULTIPLEX ASSAYS
TABLE 14 MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 15 MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 16 NORTH AMERICA: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.2.1 PLANAR PROTEIN ASSAYS
7.2.1.1 Pivotal role in drug discovery to support uptake
TABLE 17 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 18 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.2.2 BEAD-BASED PROTEIN ASSAYS
7.2.2.1 Best suited to study protein-protein interactions
TABLE 19 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 20 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.2.3 OTHER PROTEIN ASSAYS
TABLE 21 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 22 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.3 NUCLEIC ACID MULTIPLEX ASSAYS
TABLE 23 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA AND SARS-COV-2
TABLE 24 MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 25 MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 26 NORTH AMERICA: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.3.1 PLANAR NUCLEIC ACID ASSAYS
7.3.1.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
TABLE 27 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 28 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS
7.3.2.1 Increasing infectious diseases and genetic screening tests to drive market
TABLE 29 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 30 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.3.3 OTHER NUCLEIC ACID ASSAYS
TABLE 31 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 32 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
7.4 CELL-BASED MULTIPLEX ASSAYS
7.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
TABLE 33 MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 34 NORTH AMERICA: MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY (Page No. - 82)
8.1 INTRODUCTION
TABLE 35 MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
8.2 FLOW CYTOMETRY
8.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO MAKE THIS MARKET SEGMENT LARGEST
TABLE 36 MARKET FOR FLOW CYTOMETRY, BY REGION, 2020-2027 (USD MILLION)
TABLE 37 NORTH AMERICA: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020-2027 (USD MILLION)
8.3 FLUORESCENCE DETECTION
8.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL GROWTH
TABLE 38 MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2020-2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2020-2027 (USD MILLION)
8.4 LUMINESCENCE
8.4.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
TABLE 40 MARKET FOR LUMINESCENCE, BY REGION, 2020-2027 (USD MILLION)
TABLE 41 NORTH AMERICA: MARKET FOR LUMINESCENCE, BY COUNTRY, 2020-2027 (USD MILLION)
8.5 MULTIPLEX REAL-TIME PCR
8.5.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
TABLE 42 MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2020-2027 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2020-2027 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 44 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)

9 MULTIPLEX ASSAYS MARKET, BY APPLICATION (Page No. - 89)
9.1 INTRODUCTION
TABLE 46 MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
9.2 RESEARCH & DEVELOPMENT
TABLE 47 MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2020-2027 (USD MILLION)
TABLE 48 MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020-2027 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2020-2027 (USD MILLION)
9.2.1 DRUG DISCOVERY & DEVELOPMENT
9.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
TABLE 50 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020-2027 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020-2027 (USD MILLION)
9.2.2 BIOMARKER DISCOVERY & VALIDATION
9.2.2.1 Multiplex assays aid in quantitative measurement of protein biomarkers in large samples
TABLE 52 MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2020-2027 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2020-2027 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
TABLE 54 MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 55 MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)
TABLE 56 NORTH AMERICA: MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.1 INFECTIOUS DISEASES
9.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
TABLE 57 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)
TABLE 58 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.2 CANCER
9.3.2.1 Rising burden of cancer to drive market
TABLE 59 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 60 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
TABLE 61 MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.3 CARDIOVASCULAR DISEASES
9.3.3.1 High burden of cardiovascular diseases to support market growth
TABLE 63 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION)
TABLE 64 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.4 AUTOIMMUNE DISEASES
9.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
TABLE 65 PREVALENCE OF SOME AUTOIMMUNE DISEASES
TABLE 66 MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020-2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.5 NERVOUS SYSTEM DISORDERS
9.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
TABLE 68 MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2020-2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
9.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers that help in timely diagnosis of such conditions
TABLE 70 MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2020-2027 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
9.3.7 OTHER DISEASES
TABLE 72 MARKET FOR OTHER DISEASES, BY REGION, 2020-2027 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)

10 MULTIPLEX ASSAYS MARKET, BY END USER (Page No. - 105)
10.1 INTRODUCTION
TABLE 74 MARKET, BY END USER, 2020-2027 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE ITS UPTAKE
TABLE 75 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
10.3 HOSPITALS & RESEARCH INSTITUTES
10.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
TABLE 77 MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
TABLE 78 NORTH AMERICA: MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
10.4 REFERENCE LABORATORIES
10.4.1 GROWING NUMBER OF CLINICAL TESTS PERFORMED IN REFERENCE LABORATORIES AND INCREASING NUMBER OF ACCREDITED LABORATORIES TO SUPPORT MARKET GROWTH
TABLE 79 MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
TABLE 80 NORTH AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
10.5 OTHER END USERS
TABLE 81 MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)
TABLE 82 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2027 (USD MILLION)

11 MULTIPLEX ASSAYS MARKET, BY REGION (Page No. - 112)
11.1 INTRODUCTION
TABLE 83 MARKET, BY REGION, 2020-2027 (USD MILLION)
11.2 NORTH AMERICA
TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 89 NORTH AMERICA: MARKET, BY END USER, 2020-2027 (USD MILLION)
FIGURE 23 NORTH AMERICA: MARKET SNAPSHOT
11.2.1 RECESSION IMPACT ON NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 90 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 91 US: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 92 US: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 93 US: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 94 US: MARKET, BY END USER, 2020-2027 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increased funding activities by government in life sciences research & drug development to support market growth
TABLE 95 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 96 CANADA: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 97 CANADA: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 98 CANADA: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 99 CANADA: MARKET, BY END USER, 2020-2027 (USD MILLION)
11.3 EUROPE
TABLE 100 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
TABLE 101 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 102 EUROPE: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 103 EUROPE: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 104 EUROPE: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 105 EUROPE: MARKET, BY END USER, 2020-2027 (USD MILLION)
11.3.1 RECESSION IMPACT ON EUROPE
11.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT
TABLE 106 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET, BY END USER, 2020-2027 (USD MILLION)
11.4.1 RECESSION IMPACT ON ASIA PACIFIC
11.5 REST OF THE WORLD
TABLE 111 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
TABLE 112 REST OF THE WORLD: MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 113 REST OF THE WORLD: MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
TABLE 114 REST OF THE WORLD: MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 115 REST OF THE WORLD: MARKET, BY END USER, 2020-2027 (USD MILLION)
11.5.1 RECESSION IMPACT ON REST OF THE WORLD

12 COMPETITIVE LANDSCAPE (Page No. - 133)
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
TABLE 116 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017-2021)
12.4 MARKET SHARE ANALYSIS
12.4.1 MULTIPLEX ASSAYS MARKET
FIGURE 26 MARKET SHARE, BY KEY PLAYER, 2021
TABLE 117 MARKET: INTENSITY OF COMPETITIVE RIVALRY
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 27 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 28 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE SCENARIO
12.7.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020- 2023)
12.7.2 DEALS
TABLE 119 KEY DEALS (2020-2023)

13 COMPANY PROFILES (Page No. - 143)
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
13.1.1 ILLUMINA, INC.
TABLE 120 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 29 COMPANY SNAPSHOT: ILLUMINA, INC. (2022)
13.1.2 BIO-RAD LABORATORIES, INC.
TABLE 121 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2022)
13.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 122 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC. (2021)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 123 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2022)
13.1.5 DIASORIN S.P.A.
TABLE 124 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: DIASORIN S.P.A. (2021)
13.1.6 QIAGEN N.V.
TABLE 125 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2021)
13.1.7 ABCAM PLC
TABLE 126 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: ABCAM PLC (2021)
13.1.8 MERCK KGAA
TABLE 127 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2022)
13.1.9 AGILENT TECHNOLOGIES, INC.
TABLE 128 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2022)
13.1.10 QUANTERIX
TABLE 129 QUANTERIX: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: QUANTERIX (2022)
13.1.11 BIO-TECHNE
TABLE 130 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2021)
13.1.12 MESO SCALE DIAGNOSTICS, LLC
TABLE 131 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
13.1.13 RANDOX LABORATORIES LTD.
TABLE 132 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 OLINK
TABLE 133 OLINK: COMPANY OVERVIEW
13.2.2 SEEGENE INC.
TABLE 134 SEEGENE INC.: COMPANY OVERVIEW
13.2.3 SIEMENS HEALTHINEERS AG
TABLE 135 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
13.2.4 PERKINELMER INC.
TABLE 136 PERKINELMER INC.: COMPANY OVERVIEW
13.2.5 SHIMADZU CORPORATION
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
13.2.6 PROMEGA CORPORATION
TABLE 138 PROMEGA CORPORATION: COMPANY OVERVIEW
13.2.7 ENZO BIOCHEM INC.
TABLE 139 ENZO BIOCHEM INC.: COMPANY OVERVIEW
13.2.8 CAYMAN CHEMICAL
TABLE 140 CAYMAN CHEMICAL: COMPANY OVERVIEW
13.2.9 BOSTER BIOLOGICAL TECHNOLOGY
TABLE 141 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
13.2.10 ANTIGENIX AMERICA, INC.
TABLE 142 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW
13.2.11 QUANSYS BIOSCIENCES INC.
TABLE 143 QUANSYS BIOSCIENCES INC.: COMPANY OVERVIEW
13.2.12 RAYBIOTECH LIFE, INC.
TABLE 144 RAYBIOTECH LIFE, INC.: COMPANY OVERVIEW

14 APPENDIX (Page No. - 200)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS